BIOCARDIA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.392 USD | 0.00% |
|
-1.01% | -40.98% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 1.35M | Sales 2023 | 477K | Capitalization | 15.69M |
|---|---|---|---|---|---|
| Net income 2022 | -11M | Net income 2023 | -11M | EV / Sales 2022 | 26.7 x |
| Net cash position 2022 | 5.73M | Net Debt 2023 | 212K | EV / Sales 2023 | 33.3 x |
| P/E ratio 2022 |
-3.11
x | P/E ratio 2023 |
-1.22
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioCardia, Inc.
More press releases
| 1 day | +1.28% | ||
| 1 week | -1.01% | ||
| Current month | +1.27% | ||
| 1 month | +6.58% | ||
| 3 months | -7.33% | ||
| 6 months | -37.78% | ||
| Current year | -40.98% |
1 week
0.39
0.41
1 month
0.320.41
Current year
0.320.72
1 year
0.322.92
3 years
0.325.10
5 years
0.0017.50
10 years
0.00138.24
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
| Chief Tech/Sci/R&D Officer | - | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.392 | 0.00% | 15 911 |
| 24-05-20 | 0.392 | 0.00% | 49,077 |
| 24-05-17 | 0.392 | -1.04% | 65,484 |
| 24-05-16 | 0.3961 | -0.95% | 156,410 |
| 24-05-15 | 0.3999 | +0.98% | 91,213 |
Delayed Quote Nasdaq, May 21, 2024 at 10:44 am EDT
More quotes
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.98% | 10.53M | |
| +8.67% | 115B | |
| +13.31% | 107B | |
| -13.83% | 22.31B | |
| -3.78% | 21.6B | |
| -5.44% | 18.23B | |
| -38.57% | 17.62B | |
| +7.33% | 14.26B | |
| +34.09% | 12.37B | |
| -27.42% | 8.28B |
- Stock Market
- Equities
- BCDA Stock